These results indicate that partial-/non-co-occurrence of OCT4 with its three pseudogenes (POU5F1P1, POU5F1P3, and POU5F1P4) may regulate clinical outcomes in breast cancer patients. This evidence concerns the gene POU5F1 and breast cancer.